Advertisement


Daniel J. George, MD, on RCC: Study Results on Adjuvant Treatment

2018 Genitourinary Cancers Symposium

Advertisement

Daniel J. George, MD, of Duke University Medical Center, discusses phase III findings on adjuvant sunitinib in patients with high-risk renal cell carcinoma, in an exploratory pharmacogenomic analysis (Abstract 576).



Related Videos

Kidney Cancer
Immunotherapy

Sumanta K. Pal, MD, on RCC: Results From Two Clinical Trials

Sumanta K. Pal, MD, of the City of Hope Comprehensive Cancer Center, discusses phase III study findings from IMmotion151, which looked at atezolizumab plus bevacizumab vs sunitinib...

Prostate Cancer

Maha Hussain, MD, on Prostate Cancer: Results From the PROSPER Trial

Maha Hussain, MD, of Northwestern University, discusses phase III findings on enzalutamide in men with nonmetastatic castration-resistant prostate cancer (Abstract 3).

Bladder Cancer
Immunotherapy

Gregory R. Pond, PhD, on Urothelial Cancer: Advance in Prognosis

Gregory R. Pond, PhD, of McMaster University, discusses a new six-factor prognostic model for patients with advanced urothelial carcinoma receiving post platinum atezolizumab (Abst...

Kidney Cancer

Patrick Schöffski, MD, MPH, on RCC: Final Results of the EORTC 90101 CREATE Trial

Patrick Schöffski, MD, MPH, of Catholic University Leuven, discusses findings on the effect of crizotinib on disease control in patients with advanced papillary renal cell carcinom...

Solid Tumors

Jeffrey M. Holzbeierlein, MD, on Penile, Urethral, and Testicular Cancers: Abstract Roundup

Jeffrey M. Holzbeierlein, MD, of the University of Kansas Medical Center, summarizes key abstracts on long-term sexual function in germ cell tumor survivors, sentinel node biopsy i...

Advertisement

Advertisement



Advertisement